Evoqua Water Technologies Reports First Quarter 2021 Results
Evoqua Water Technologies (NYSE:AQUA) reported a 6.9% decline in first-quarter revenue for fiscal 2021, totaling $322.2 million, down from $346.1 million year-over-year. The decrease was partially attributed to the divestiture of the Memcor product line and organic revenue drop of 3.5% due to pandemic-related impacts. Net income fell to $6.5 million with diluted EPS of $0.05, compared to $53.5 million and $0.44 EPS last year. Adjusted EBITDA rose to $44.8 million. The company anticipates continued uneven market demand amid ongoing COVID-19 challenges.
- Adjusted EBITDA increased to $44.8 million, up from $43.6 million year-over-year.
- Strong order pipeline and organic orders growth reported.
- Maintained solid free cash flow.
- Revenue decreased by 6.9%, from $346.1 million to $322.2 million.
- Net income significantly dropped from $53.5 million to $6.5 million.
- Diluted EPS fell from $0.44 to $0.05.
- Organic revenue decreased by 3.5%, attributed to pandemic impacts.
Evoqua Water Technologies (NYSE:AQUA), an industry leader in mission-critical water treatment solutions, today reported results for its first quarter ended December 31, 2020.
Revenue for the first quarter of fiscal 2021 was
“We reported solid first quarter results while navigating varying demand trends across our end markets amid ongoing COVID-19 challenges. Our organization is focused on engaging with our customers and delivering solutions and technologies that address increasingly complex water treatment problems. Organic orders grew, our pipeline remains solid, and our book to bill ratio remains above 1.0.” said Mr. Ron Keating, Evoqua’s CEO.
Mr. Keating continued, “We continue to prioritize the health and safety of our team members, maintaining customer continuity and service excellence, and improving our balance sheet flexibility. Our team has responded well and our first quarter financial results were largely as expected. We note strength in adjusted EBITDA growth and margin as well as solid free cash flow. Our strong order book will continue to drive investments in organic growth opportunities and technology expansion.”
Mr. Keating stated, “We expect continued uneven market demand due to COVID-19 with visibility across the full year remaining somewhat limited. Our focus will remain on delivering organic growth through outsourced water solutions, wastewater recycle/reuse, Water One® digitally enabled systems and selling our broad portfolio of component technologies. We expect M&A to supplement our organic growth strategy, and we welcome the employees of Ultrapure & Industrial Services, our latest acquisition, to the Evoqua family. Our sustainability initiatives are gaining traction, and we are providing solutions to help our customers meet their sustainable objectives. We look forward to publishing our 2020 Sustainability Report this Spring.”
First Quarter Segment Results
Evoqua has two reportable operating segments - Integrated Solutions and Services and Applied Product Technologies. The results of our segments for the first quarter are as follows:
Integrated Solutions and Services
Segment revenues decreased
-
Service revenues decreased
$6.9 million as compared to the prior year period, primarily driven by temporary delays in annual maintenance in the oil and gas refining end market, the timing of completion of certain large projects in the prior year and shutdowns and delays due to COVID-19. Price realization related to established service contracts and service growth in the healthcare and pharmaceuticals end markets partially offset these declines. -
Capital revenues declined
$4.0 million as compared to the prior year period, primarily related to the timing of projects in the microelectronics end market, which was partially offset by new projects across a variety of end markets. -
The remaining decrease was due to a reduction in aftermarket revenue of
$2.5 million .
Operating profit decreased by
-
Segment profitability decreased by
$7.3 million as compared to the prior year period driven by lower volume and mix, lower productivity due to customer shutdowns and enhanced safety protocols as a result of the COVID-19 pandemic, and increased operating costs based on changes in allocation methodologies for corporate expenses. These declines were partially offset by additional price realization in the current period. -
Positive drivers to profitability were associated with a decrease in travel and discretionary spending of
$1.7 million . -
Depreciation and amortization expense increased by
$1.2 million compared to the prior year period as the segment continues to invest in revenue generating assets.
Segment adjusted EBITDA decreased
Applied Product Technologies
Segment revenues decreased by
-
The divestiture of the Memcor product line resulted in a reduction in revenue of
$14.4 million as compared to the prior year period. -
Revenues increased
$6.0 million in the Asia Pacific region as compared to the prior year period. This volume increase was partially offset by revenue declines across multiple product lines in both the Americas and EMEA regions by$0.6 million and$3.7 million , respectively, as compared to the prior year period, mainly due to continued customer site access challenges and delays primarily impacting the Municipal Drinking Water and Aquatics end markets. -
Foreign currency translation resulted in a favorable revenue impact of
$2.2 million as compared to the prior year period.
Operating profit decreased
-
The decline in segment profitability was primarily related to the net pre-tax benefit on sale of the Memcor product line of
$49.0 million in the prior year period. Operating profit was also impacted by a$1.2 million decrease related to the reduction in revenue volume as a result of the divestiture. -
Organic volume as well as improvement in operational efficiencies and cost containment measures, partially offset by the impact of variances in product mix, contributed a net
$4.7 million in profitability as compared to the prior year period, while inflation and employee related costs reduced operating profit by$0.9 million . -
Operating profit was benefited
$0.5 million by foreign currency translation as compared to the prior year period. -
Further net operating profit decrease of
$3.8 million was attributable to higher restructuring costs and changes in other non-recurring activity as compared to the prior year period.
Segment adjusted EBITDA increased
First Quarter Earnings Call and Webcast
The Company will hold its first quarter fiscal 2021 earnings conference call Tuesday, February 2, 2021, at 10:00 a.m. E.T. The live audio webcast and presentation slides for the call will be accessible via Evoqua’s Investor Relations website, http://aqua.evoqua.com/.
Conference telephone number:
US Participant Dial-in: (866) 690-2108
International Participant Dial-in: (918) 398-8081
Conference ID: 3280356
The link to the webcast replay as well as the presentation slides will also be posted on Evoqua’s Investor Relations website.
US Replay: (855) 859-2056
International Replay: (404) 537-3406
Replay available: Beginning 1:00 p.m. ET on February 2 until 11:59 p.m. on February 16, 2021
Conference ID: 3280356
About Evoqua Water Technologies
Evoqua Water Technologies is a leading provider of mission critical water and wastewater treatment solutions, offering a broad portfolio of products, services and expertise to support industrial, municipal and recreational customers who value water. Evoqua has worked to protect water, the environment and its employees for more than 100 years, earning a reputation for quality, safety and reliability around the world. Headquartered in Pittsburgh, Pennsylvania, the company operates in more than 160 locations across ten countries. Serving more than 38,000 customers and 200,000 installations worldwide, our employees are united by a common purpose: Transforming Water. Enriching Life.
Use of Non-GAAP Financial Measures
This press release contains “non-GAAP financial measures,” which are adjusted financial measures that are not calculated and presented in accordance with generally accepted accounting principles in the United States, or “GAAP.” These non-GAAP adjusted financial measures are provided as additional information for investors. We believe these non-GAAP adjusted financial measures, which include organic and inorganic revenue and adjusted EBITDA, are helpful to management and investors in highlighting trends in our operating results and provide greater clarity and comparability period over period to management and our investors regarding the operational impact of long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. The presentation of this additional information is not meant to be considered in isolation or as a substitute for GAAP measures. For reconciliations of the non-GAAP adjusted financial measures used in this press release to the most directly comparable respective GAAP measures, see the “Use of Non-GAAP Measures” section below.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All of these forward-looking statements are based on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control. These and other important factors may cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements, or could affect our share price. Some of the factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements include among other things, general global economic and business conditions, including the impacts of the COVID-19 pandemic and disruptions in global oil markets; our ability to compete successfully in our markets; our ability to execute projects on budget and on schedule; the potential for us to incur liabilities to customers as a result of warranty claims or failure to meet performance guarantees; our ability to meet our customers’ safety standards or the potential for adverse publicity affecting our reputation as a result of incidents such as workplace accidents, mechanical failures, spills, uncontrolled discharges, damage to customer or third-party property or the transmission of contaminants or diseases; our ability to continue to develop or acquire new products, services and solutions and adapt our business to meet the demands of our customers, comply with changes to government regulations and achieve market acceptance with acceptable margins; our ability to implement our growth strategy, including acquisitions and our ability to identify suitable acquisition targets; our ability to operate or integrate any acquired businesses, assets or product lines profitably or otherwise successfully implement our growth strategy; our ability to achieve the expected benefits of our restructuring actions, including restructuring our business into two segments; material and other cost inflation and our ability to mitigate the impact of inflation by increasing selling prices and improving our productivity efficiencies; our ability to accurately predict the timing of contract awards; delays in enactment or repeals of environmental laws and regulations; the potential for us to become subject to claims relating to handling, storage, release or disposal of hazardous materials; our ability to retain our senior management and other key personnel; our increasing dependence on the continuous and reliable operation of our information technology systems; risks associated with product defects and unanticipated or improper use of our products; litigation, regulatory or enforcement actions and reputational risk as a result of the nature of our business or our participation in large-scale projects; seasonality of sales and weather conditions; risks related to government customers, including potential challenges to our government contracts or our eligibility to serve government customers; the potential for our contracts with federal, state and local governments to be terminated or adversely modified prior to completion; risks related to foreign, federal, state and local environmental, health and safety laws and regulations and the costs associated therewith; risks associated with international sales and operations, including our operations in China; our ability to adequately protect our intellectual property from third-party infringement; risks related to our substantial indebtedness; our need for a significant amount of cash, which depends on many factors beyond our control; risks related to AEA Investors LP’s ownership interest in us; and other factors described in the “Risk Factors” section included in our Annual Report on Form 10-K for the fiscal year ended September 30, 2020, as filed with the SEC on November 20, 2020, and in other periodic reports we file with the SEC. All statements other than statements of historical fact included in this press release are forward-looking statements, including, but not limited to, expectations for fiscal 2021 and statements related to the COVID-19 pandemic, the impact of which remains inherently uncertain. Additionally, any forward-looking statements made in this press release speak only as of the date of this release. We undertake no obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements made herein, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.
EVOQUA WATER TECHNOLOGIES CORP. |
||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) |
||||||||
(In thousands, except per share amounts) |
||||||||
|
Three Months Ended
|
|||||||
|
2020 |
|
2019 |
|||||
Revenue from product sales and services |
$ |
322,193 |
|
|
$ |
346,105 |
|
|
Cost of product sales and services |
(226,848 |
) |
|
(240,390 |
) |
|||
Gross profit |
95,345 |
|
|
105,715 |
|
|||
General and administrative expense |
(42,283 |
) |
|
(45,770 |
) |
|||
Sales and marketing expense |
(33,928 |
) |
|
(38,014 |
) |
|||
Research and development expense |
(3,123 |
) |
|
(3,684 |
) |
|||
Total operating expenses |
(79,334 |
) |
|
(87,468 |
) |
|||
Other operating income, net |
223 |
|
|
51,445 |
|
|||
Income before interest expense and income taxes |
16,234 |
|
|
69,692 |
|
|||
Interest expense |
(8,673 |
) |
|
(13,583 |
) |
|||
Income before income taxes |
7,561 |
|
|
56,109 |
|
|||
Income tax expense |
(1,084 |
) |
|
(2,603 |
) |
|||
Net income |
6,477 |
|
|
53,506 |
|
|||
Net income attributable to non‑controlling interest |
44 |
|
|
361 |
|
|||
Net income attributable to Evoqua Water Technologies Corp. |
$ |
6,433 |
|
|
$ |
53,145 |
|
|
Basic income per common share |
$ |
0.05 |
|
|
$ |
0.46 |
|
|
Diluted income per common share |
$ |
0.05 |
|
|
$ |
0.44 |
|
|
EVOQUA WATER TECHNOLOGIES CORP. |
||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
||||||||
(In thousands, except per share amounts) |
||||||||
|
(Unaudited) |
|
|
|||||
|
December 31,
|
|
September 30,
|
|||||
ASSETS |
|
|
|
|||||
Current assets |
$ |
679,540 |
|
|
$ |
695,712 |
|
|
Cash and cash equivalents |
197,920 |
|
|
193,001 |
|
|||
Receivables, net |
246,211 |
|
|
260,479 |
|
|||
Inventories, net |
155,026 |
|
|
142,379 |
|
|||
Contract assets |
59,825 |
|
|
80,759 |
|
|||
Other current assets |
20,558 |
|
|
19,094 |
|
|||
Property, plant, and equipment, net |
369,915 |
|
|
364,461 |
|
|||
Goodwill |
408,593 |
|
|
397,205 |
|
|||
Intangible assets, net |
302,557 |
|
|
309,967 |
|
|||
Operating lease right-of-use assets, net |
48,245 |
|
|
45,965 |
|
|||
Other non-current assets |
34,816 |
|
|
31,148 |
|
|||
Total assets |
$ |
1,843,666 |
|
|
$ |
1,844,458 |
|
|
LIABILITIES AND EQUITY |
|
|
|
|||||
Current liabilities |
$ |
326,126 |
|
|
$ |
349,555 |
|
|
Accounts payable |
141,931 |
|
|
153,890 |
|
|||
Current portion of debt, net of deferred financing fees |
18,426 |
|
|
14,339 |
|
|||
Contract liabilities |
34,445 |
|
|
26,259 |
|
|||
Accrued expenses and other liabilities |
120,668 |
|
|
143,389 |
|
|||
Other current liabilities |
10,656 |
|
|
11,678 |
|
|||
Non-current liabilities |
1,015,579 |
|
|
1,012,840 |
|
|||
Long-term debt, net of deferred financing fees |
860,215 |
|
|
861,695 |
|
|||
Obligation under operating leases |
39,897 |
|
|
37,796 |
|
|||
Other non-current liabilities |
115,467 |
|
|
113,349 |
|
|||
Total liabilities |
1,341,705 |
|
|
1,362,395 |
|
|||
Shareholders’ equity |
|
|
|
|||||
Common stock, par value |
1,202 |
|
|
1,189 |
|
|||
Treasury stock: 2,196 shares at December 31, 2020 and 2,195 shares at September 30, 2020 |
(2,837 |
) |
|
(2,837 |
) |
|||
Additional paid-in capital |
582,197 |
|
|
564,928 |
|
|||
Retained deficit |
(56,231 |
) |
|
(62,664 |
) |
|||
Accumulated other comprehensive loss, net of tax |
(24,083 |
) |
|
(20,472 |
) |
|||
Total Evoqua Water Technologies Corp. equity |
500,248 |
|
|
480,144 |
|
|||
Non-controlling interest |
1,713 |
|
|
1,919 |
|
|||
Total shareholders’ equity |
501,961 |
|
|
482,063 |
|
|||
Total liabilities and shareholders’ equity |
$ |
1,843,666 |
|
|
$ |
1,844,458 |
|
|
EVOQUA WATER TECHNOLOGIES CORP. |
||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CASH FLOWS (Unaudited) |
||||||||
(In thousands) |
||||||||
|
Three Months Ended
|
|||||||
|
2020 |
|
2019 |
|||||
Operating activities |
|
|
|
|||||
Net income |
$ |
6,477 |
|
|
$ |
53,506 |
|
|
Reconciliation of net income to cash flows provided by operating activities: |
|
|
|
|||||
Depreciation and amortization |
27,391 |
|
|
25,143 |
|
|||
Amortization of deferred financing fees |
526 |
|
|
701 |
|
|||
Deferred income taxes |
258 |
|
|
(679 |
) |
|||
Share-based compensation |
3,019 |
|
|
3,680 |
|
|||
Loss on sale of property, plant and equipment |
19 |
|
|
173 |
|
|||
Gain on sale of business |
— |
|
|
(58,279 |
) |
|||
Foreign currency exchange gains on intercompany loans and other non-cash items |
(6,459 |
) |
|
(6,086 |
) |
|||
Changes in assets and liabilities |
(15,617 |
) |
|
(13,427 |
) |
|||
Net cash provided by operating activities |
15,614 |
|
|
4,732 |
|
|||
Investing activities |
|
|
|
|||||
Purchase of property, plant and equipment |
(17,260 |
) |
|
(17,572 |
) |
|||
Purchase of intangibles |
(81 |
) |
|
(210 |
) |
|||
Proceeds from sale of property, plant and equipment |
127 |
|
|
251 |
|
|||
Proceeds from sale of business, net of cash of |
— |
|
|
108,921 |
|
|||
Acquisitions |
(8,743 |
) |
|
(11,160 |
) |
|||
Net cash (used in) provided by investing activities |
(25,957 |
) |
|
80,230 |
|
|||
Financing activities |
|
|
|
|||||
Issuance of debt, net of deferred issuance costs |
7,805 |
|
|
3,532 |
|
|||
Borrowings under credit facility |
— |
|
|
13 |
|
|||
Repayment of debt |
(5,723 |
) |
|
(3,793 |
) |
|||
Repayment of finance lease obligation |
(3,821 |
) |
|
(4,162 |
) |
|||
Payment of earn-out related to previous acquisitions |
— |
|
|
(175 |
) |
|||
Proceeds from issuance of common stock |
14,263 |
|
|
4,046 |
|
|||
Distribution to non‑controlling interest |
(250 |
) |
|
(1,250 |
) |
|||
Net cash provided by (used in) financing activities |
12,274 |
|
|
(1,789 |
) |
|||
Effect of exchange rate changes on cash |
2,988 |
|
|
1,849 |
|
|||
Change in cash and cash equivalents |
4,919 |
|
|
85,022 |
|
|||
Cash and cash equivalents |
|
|
|
|||||
Beginning of period |
193,001 |
|
|
109,881 |
|
|||
End of period |
$ |
197,920 |
|
|
$ |
194,903 |
|
|
Use of Non-GAAP Measures
The Company reports its financial results in accordance with U.S. generally accepted accounting principles (“GAAP”). However, management believes that certain non-GAAP financial measures provide users of the Company's financial information with additional useful information in evaluating operating performance. We use the non-GAAP financial measures “EBITDA,” “adjusted EBITDA,” and “organic revenue” in evaluating our past performance and future prospects. EBITDA is defined as net income (loss) before interest expense, income tax benefit (expense) and depreciation and amortization. Adjusted EBITDA is defined as net income (loss) before interest expense, income tax benefit (expense) and depreciation and amortization, adjusted for the impact of certain other items, including restructuring and related business transformation costs, purchase accounting adjustment costs, non-cash share-based compensation, transaction costs and other gains, losses and expenses.
Adjusted EBITDA is one of the primary metrics used by management to evaluate the financial performance of our business. We present adjusted EBITDA because we believe it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry. Further, we believe it is helpful in highlighting trends in our operating results and provides greater clarity and comparability period over period to management and our investors regarding the operational impact of long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management uses adjusted EBITDA to supplement GAAP measures of performance as follows:
- to assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance;
- in our management incentive compensation, which is based in part on components of adjusted EBITDA;
- in certain calculations under our senior secured credit facilities, which use components of adjusted EBITDA;
- to evaluate the effectiveness of our business strategies;
- to make budgeting decisions; and
- to compare our performance against that of other peer companies using similar measures.
In addition to the above, our chief operating decision maker uses EBITDA and adjusted EBITDA of each reportable operating segment to evaluate the operating performance of such segments. EBITDA and adjusted EBITDA of the reportable operating segments do not include certain charges that are presented within corporate activities. These charges include certain restructuring and other business transformation charges that have been incurred to align and reposition the Company to the current reporting structure, acquisition related costs (including transaction costs and certain integration costs) and share-based compensation charges.
You are encouraged to evaluate each adjustment and the reasons we consider it appropriate for supplemental analysis. In addition, in evaluating adjusted EBITDA, you should be aware that in the future, we may incur expenses similar to the adjustments in the presentation of adjusted EBITDA. Our presentation of adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. In addition, adjusted EBITDA may not be comparable to similarly titled measures used by other companies in our industry or across different industries.
Organic revenue is another metric used by management to evaluate the performance of our business. Organic revenue is defined as revenues excluding the impact of foreign exchange and inorganic revenue. Inorganic revenue is defined as revenues from acquisitions and divestitures. We present organic revenue as we believe it is helpful to management and investors in highlighting trends in our revenues excluding the impacts of acquisitions, divestitures and foreign currency translation.
The following is a reconciliation of our Net income to Adjusted EBITDA (unaudited):
|
Three Months Ended
|
|
|
||||||||
(In millions) |
2020 |
|
2019 |
|
% Variance |
||||||
Net income |
$ |
6.5 |
|
|
$ |
53.5 |
|
|
(87.9 |
)% |
|
Income tax expense |
1.1 |
|
|
2.6 |
|
|
(57.7 |
)% |
|||
Interest expense |
8.7 |
|
|
13.6 |
|
|
(36.0 |
)% |
|||
Operating profit |
16.3 |
|
|
69.7 |
|
|
(76.6 |
)% |
|||
Depreciation and amortization |
27.4 |
|
|
25.1 |
|
|
9.2 |
% |
|||
EBITDA |
43.7 |
|
|
94.8 |
|
|
(53.9 |
)% |
|||
Restructuring and related business transformation costs (a) |
1.8 |
|
|
1.7 |
|
|
5.9 |
% |
|||
Share-based compensation (b) |
3.1 |
|
|
3.7 |
|
|
(16.2 |
)% |
|||
Transaction costs (c) |
0.6 |
|
|
0.2 |
|
|
200.0 |
% |
|||
Other (gains) losses and expenses (d) |
(4.4 |
) |
|
(56.8 |
) |
|
(92.3 |
)% |
|||
Adjusted EBITDA |
$ |
44.8 |
|
|
$ |
43.6 |
|
|
2.8 |
% |
|
(a) |
|
Restructuring and related business transformation costs |
||||
|
|
Adjusted EBITDA is calculated prior to considering certain restructuring or business transformation events. These events may occur over extended periods of time, and in some cases it is reasonably possible that they could reoccur in future periods based on reorganizations of the business, cost reduction or productivity improvement needs, or in response to economic conditions. For the periods presented such events include the following: |
||||
|
|
(i) |
Certain costs and expenses in connection with various restructuring initiatives, including severance costs, relocation costs, recruiting expenses, and third-party consultant costs to assist with these initiatives. This includes: |
|||
|
|
|
(A) |
amounts related to the Company’s restructuring initiatives to reduce the cost structure and rationalize location footprint following the sale of the Memcor product line; |
||
|
|
|
(B) |
amounts related to the Company’s transition from a three-segment structure to a two-segment operating model designed to better serve the needs of customers worldwide; and |
||
|
|
|
(C) |
amounts related to various other initiatives implemented to restructure and reorganize our business with the appropriate management team and cost structure. |
||
Three Months Ended
|
||||||||
(In millions) |
2020 |
|
2019 |
|||||
Post Memcor divestiture restructuring(1) |
$ |
0.9 |
|
|
$ |
— |
|
|
Cost of product sales and services ("Cost of sales") |
0.8 |
|
|
— |
|
|||
S&M expense |
0.2 |
|
|
— |
|
|||
Other operating (income) expense |
(0.1 |
) |
|
— |
|
|||
Two-segment restructuring(2) |
$ |
0.2 |
|
|
$ |
1.0 |
|
|
Cost of sales |
— |
|
|
0.3 |
|
|||
G&A expense |
0.2 |
|
|
0.3 |
|
|||
Other operating (income) expense |
— |
|
|
0.4 |
|
|||
Various other initiatives(3) |
$ |
— |
|
|
$ |
0.2 |
|
|
Cost of sales |
— |
|
|
0.1 |
|
|||
G&A expense |
— |
|
|
0.1 |
|
|||
Total |
$ |
1.1 |
|
|
$ |
1.2 |
|
|
|
|
(1) |
all of which is reflected in restructuring charges in Note 14, “Restructuring and Related Charges,” to our Consolidated Financial Statements to be included in our Quarterly Report on Form 10-Q for the three months ended December 31, 2020 (the “Restructuring Footnote”). |
||
|
|
|
(2) |
of which |
|
|
|
|
(3) |
all of which is reflected in the Restructuring Footnote for the three months ended December 31, 2019. |
|
|
(ii) |
Legal settlement costs and intellectual property related fees associated with legacy matters prior to the AEA Acquisition, including fees and settlement costs related to product warranty litigation on MEMCOR® products and certain discontinued products. This includes: |
|||
Three Months Ended
|
|||||||
(In millions) |
2020 |
|
2019 |
||||
Cost of sales |
$ |
— |
|
|
$ |
0.1 |
|
G&A expense |
0.1 |
|
|
— |
|
||
Total |
$ |
0.1 |
|
|
$ |
0.1 |
|
|
|
(iii) |
Expenses associated with our information technology and functional infrastructure transformation subsequent to the AEA Acquisition, including activities to optimize information technology systems and functional infrastructure processes. This includes: |
|
Three Months Ended
|
||||||
(In millions) |
2020 |
|
2019 |
||||
Cost of sales |
$ |
— |
|
|
$ |
0.1 |
|
G&A expense |
0.2 |
|
|
0.3 |
|
||
Total |
$ |
0.2 |
|
|
$ |
0.4 |
|
|
|
(iv)
|
Costs associated with the secondary public offering of common stock held by certain shareholders of the Company, as well as costs incurred by us in connection with establishment of our public company compliance structure and processes, including consultant costs. This includes: |
|
Three Months Ended
|
||||||
(In millions) |
2020 |
|
2019 |
||||
G&A expense |
$ |
0.4 |
|
|
$ |
— |
|
Total |
$ |
0.4 |
|
|
$ |
— |
|
(b) |
Share-based compensation |
|
|
Adjusted EBITDA is calculated prior to considering non-cash share-based compensation expenses related to equity awards. See Note 17, “Share-Based Compensation,” to our Consolidated Financial Statements to be included in our Quarterly Report on Form 10-Q for the three months ended December 31, 2020 for further detail. |
|
(c) |
Transaction related costs |
|
|
Adjusted EBITDA is calculated prior to considering transaction, integration and restructuring costs associated with business combinations because these costs are unique to each transaction and represent costs that were incurred as a result of the transaction decision. Such costs may include, without limitation, consulting and legal costs associated with due diligence and closing a transaction, restructuring and integration costs such as severance, facility consolidation costs, product rationalization or inventory obsolescence charges, system integration or conversion costs, fair value changes associated with contingent consideration, and costs associated with any litigation matters that arise subsequent to our acquisition of a business for which the matter in question preceded the transaction, but was not known, not probable or unresolved at the date of acquisition. We believe that viewing earnings prior to considering these charges provides investors with useful additional perspective because the significant costs incurred in connection with business combinations result primarily from the need to eliminate duplicate assets, activities or employees - a natural result of acquiring or disposing a fully integrated set of activities. Integration and restructuring costs associated with a business combination may occur over several years. This includes: |
|
Three Months Ended
|
||||||
(In millions) |
2020 |
|
2019 |
||||
Cost of sales |
$ |
0.1 |
|
|
$ |
0.1 |
|
G&A expense |
0.5 |
|
|
0.4 |
|
||
Other operating (income) expense |
— |
|
|
(0.3) |
|
||
Total |
$ |
0.6 |
|
|
$ |
0.2 |
|
(d) |
|
Other (gains), losses and expenses |
|
|
|
Adjusted EBITDA is calculated prior to considering certain other significant (gains), losses and expenses. Such significant items represent substantive and/or unusual items that are evaluated on an individual basis. Such evaluation considers both the quantitative and qualitative aspects of their nature and they may be highly variable and difficult to predict. Unusual items may represent items that are not part of our ongoing business, items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis, items that would be non-recurring, or items related to products we no longer sell. While not all-inclusive, examples of items that could be included as other (gains), losses and expenses would be amounts related to non-cash foreign currency exchange gains and losses on intercompany loans, significant warranty events, and certain disposals of businesses, products or facilities that do not qualify as discontinued operations under GAAP. For the periods presented such events include the following: |
|
|
(i) |
impact of foreign exchange gains and losses; |
|
|
(ii) |
foreign exchange impact related to headquarter allocations; |
|
|
(iii) |
net expense reduction related to the remediation of manufacturing defects caused by a third-party vendor for which partial restitution was received; |
|
|
(iv) |
charges incurred by the Company related to product rationalization in its electro-chlorination business; |
|
|
(v) |
trailing costs incurred in the three months ended December 31, 2020 related to the prior year sale of the Memcor product line and the net pre-tax benefit on the sale of the Memcor product line, which is net of |
|
|
(vi) |
expenses incurred by the Company as a result of the COVID-19 pandemic, including additional charges for personal protective equipment, increased costs for facility sanitization and one-time payments to certain employees; and |
|
|
(vii) |
legal fees incurred in excess of amounts covered by the Company’s insurance related to the Securities Litigation and SEC investigation. |
Other (gains), losses and expenses include the following for the periods presented below:
Three Months Ended December 31, 2020 |
|||||||||||||||||||||||||||||||
|
Other Adjustments |
||||||||||||||||||||||||||||||
(In millions) |
(i) |
|
(ii) |
|
(iii) |
|
(iv) |
|
(v) |
|
(vi) |
|
(vii) |
|
Total |
||||||||||||||||
Cost of sales |
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
0.2 |
|
|
$ |
0.2 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
0.4 |
|
G&A expense |
(6.8 |
) |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
0.1 |
|
|
1.9 |
|
|
(4.8 |
) |
||||||||
Total |
$ |
(6.8 |
) |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
0.2 |
|
|
$ |
0.2 |
|
|
$ |
0.1 |
|
|
$ |
1.9 |
|
|
$ |
(4.4 |
) |
Three Months Ended December 31, 2019 |
|||||||||||||||||||||||||||||||
|
Other Adjustments |
||||||||||||||||||||||||||||||
(In millions) |
(i) |
|
(ii) |
|
(iii) |
|
(iv) |
|
(v) |
|
(vi) |
|
(vii) |
|
Total |
||||||||||||||||
Cost of sales |
$ |
(0.4 |
) |
|
$ |
— |
|
|
$ |
0.2 |
|
|
$ |
0.1 |
|
|
$ |
0.1 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
G&A expense |
(6.2 |
) |
|
0.1 |
|
|
— |
|
|
— |
|
|
0.9 |
|
|
— |
|
|
— |
|
|
(5.2 |
) |
||||||||
Other operating (income) expense |
— |
|
|
— |
|
|
(1.6 |
) |
|
— |
|
|
(50.0 |
) |
|
— |
|
|
— |
|
|
(51.6 |
) |
||||||||
Total |
$ |
(6.6 |
) |
|
$ |
0.1 |
|
|
$ |
(1.4 |
) |
|
$ |
0.1 |
|
|
$ |
(49.0 |
) |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
(56.8 |
) |
Adjusted EBITDA on a segment basis is defined as earnings before interest expense, income tax benefit (expense) and depreciation and amortization, adjusted for the impact of certain other items that have been reflected at the segment level. The following is a reconciliation of our segment operating profit to our segment adjusted EBITDA:
|
Three Months Ended December 31, |
||||||||||||||
|
2020 |
|
2019 |
||||||||||||
(In millions) |
Integrated
|
|
Applied
|
|
Integrated
|
|
Applied
|
||||||||
Operating Profit |
$ |
26.4 |
|
|
$ |
13.4 |
|
|
$ |
33.2 |
|
|
$ |
63.1 |
|
Depreciation and amortization |
16.8 |
|
|
3.6 |
|
|
15.6 |
|
|
3.6 |
|
||||
EBITDA |
$ |
43.2 |
|
|
$ |
17.0 |
|
|
$ |
48.8 |
|
|
$ |
66.7 |
|
Restructuring and related business transformation costs (a) |
— |
|
|
1.6 |
|
|
— |
|
|
0.7 |
|
||||
Transaction costs (b) |
— |
|
|
— |
|
|
— |
|
|
(1.3 |
) |
||||
Other losses (gains) and expenses (c) |
— |
|
|
0.4 |
|
|
— |
|
|
(50.3 |
) |
||||
Adjusted EBITDA |
$ |
43.2 |
|
|
$ |
19.0 |
|
|
$ |
48.8 |
|
|
$ |
15.8 |
|
(a) |
Represents costs and expenses in connection with restructuring initiatives distinct to our Applied Product Technologies segment in the three months ended December 31, 2020 and 2019, respectively. Such expenses are primarily composed of severance and relocation costs. |
|
(b) |
Represents costs associated with a change in the current estimate of certain acquisitions achieving their earn-out targets, which resulted in a decrease to the fair valued amount of the earn-out recorded upon acquisition, in the three months ended December 31, 2019, distinct to our Applied Product Technologies segment. |
|
(c) |
Other losses, (gains) and expenses, as discussed above, distinct to our Integrated Solutions and Services and Applied Product Technologies segments include the following: |
Three Months Ended December 31, |
||||||||||||||||
|
2020 |
|
2019 |
|||||||||||||
(In millions) |
Integrated
|
|
Applied
|
|
Integrated
|
|
Applied
|
|||||||||
Trailing costs from the sale of the Memcor product line |
$ |
— |
|
|
$ |
0.2 |
|
|
$ |
— |
|
|
$ |
— |
|
|
Net pre-tax benefit on sale of the Memcor product line |
— |
|
|
— |
|
|
— |
|
|
(49.0 |
) |
|||||
Remediation of manufacturing defects |
— |
|
|
— |
|
|
— |
|
|
(1.4 |
) |
|||||
Product rationalization in electro-chlorination business |
— |
|
|
0.2 |
|
|
— |
|
|
0.1 |
|
|||||
Total |
$ |
— |
|
|
$ |
0.4 |
|
|
$ |
— |
|
|
$ |
(50.3 |
) |
|
Revenue by Source
Information regarding revenues disaggregated by source of revenue and segment is as follows:
|
Three Months Ended December 31, |
|
|
||||||||||||||||||||||||
|
2020 |
|
2019 |
|
|
||||||||||||||||||||||
(In thousands) |
Integrated
|
|
Applied
|
|
Total |
|
Integrated
|
|
Applied
|
|
Total |
|
% Growth
|
||||||||||||||
Revenue from capital projects |
$ |
50,626 |
|
|
$ |
76,889 |
|
|
$ |
127,515 |
|
|
$ |
54,620 |
|
|
$ |
74,926 |
|
|
$ |
129,546 |
|
|
(1.6) |
% |
|
Revenue from aftermarket |
27,146 |
|
|
25,354 |
|
|
52,500 |
|
|
29,673 |
|
|
37,341 |
|
|
67,014 |
|
|
(21.7) |
% |
|||||||
Revenue from service |
136,945 |
|
|
5,233 |
|
|
142,178 |
|
|
143,845 |
|
|
5,700 |
|
|
149,545 |
|
|
(4.9) |
% |
|||||||
Total |
$ |
214,717 |
|
|
$ |
107,476 |
|
|
$ |
322,193 |
|
|
$ |
228,138 |
|
|
$ |
117,967 |
|
|
$ |
346,105 |
|
|
(6.9) |
% |
|
Revenue by Driver
The following is a reconciliation of revenue by driver for the three months ended December 31, 2020. Organic revenue is defined as revenues excluding the impact of foreign exchange and inorganic revenue. Inorganic revenue is defined revenues from acquisitions and divestitures.
|
Total Revenue |
|
Foreign Currency |
|
Inorganic Revenue(1) |
|
Organic Revenue |
|||||||||||||||||||||
(In millions) |
Q1'20 |
|
Q1'21 |
|
%
|
|
Q1'20 |
|
Q1'21 |
|
%
|
|
Q1'20 |
|
Q1'21 |
|
%
|
|
Q1'20 |
|
Q1'21 |
|
%
|
|||||
Evoqua Water Technologies |
|
|
(6.9) |
% |
|
$— |
|
0.6 |
% |
|
|
|
(4.1) |
% |
|
|
|
(3.5) |
% |
|||||||||
Integrated Solutions & Services |
|
|
(5.9) |
% |
|
$— |
$— |
— |
% |
|
$— |
|
0.1 |
% |
|
|
|
(6.0) |
% |
|||||||||
Applied Product Technologies |
|
|
(8.9) |
% |
|
$— |
|
1.8 |
% |
|
|
$— |
(12.2) |
% |
|
|
|
1.4 |
% |
|||||||||
(1) |
Includes divestiture of the Memcor product line on December 31, 2019, acquisition of Aquapure Technologies on September 3, 2020 and acquisition of Ultrapure & Industrial Services on December 17, 2020. |
Immaterial rounding differences may be present in the tables above.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005311/en/
FAQ
What were Evoqua Water Technologies' first-quarter results for fiscal 2021?
How did COVID-19 impact Evoqua's revenue?
What is Evoqua's diluted EPS for the first quarter of fiscal 2021?
How has Evoqua's adjusted EBITDA changed in the first quarter of fiscal 2021?
What is the outlook for Evoqua amid ongoing market challenges?
